The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2020 | PROOF: infigratinib as first-line therapy in patients with advanced CCA
Ghassan Abou-Alfa, MD, of Memorial Sloan-Kettering Cancer Center, New York City, NY, evaluates rationale and study design of the Phase III PROOF study (NCT03773302), investigating infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusions/translocations This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
